Remove trial restrictions ▶ Start for $1

Serving leading biopharmaceutical companies globally:

McKesson
Dow
McKinsey
AstraZeneca
Merck
Express Scripts

Last Updated: May 26, 2022

CLINICAL TRIALS PROFILE FOR ERLEADA


✉ Email this page to a colleague

« Back to Dashboard

All Clinical Trials for Erleada

Trial ID Title Status Sponsor Phase Start Date Summary
NCT02366494 ↗ Micro RNAs to Predict Response to Androgen Deprivation Therapy Active, not recruiting Medical College of Wisconsin 2015-04-29 Identify exosomal micro RNA that predict responses to ADT
NCT03009981 ↗ A Study of Androgen Annihilation in High-Risk Biochemically Relapsed Prostate Cancer Recruiting Janssen Research & Development, LLC Phase 3 2017-03-06 This is a randomized, open-label, three-arm, phase 3 study in men with biochemically recurrent prostate cancer and PSA doubling time ≤ 9 months at the time of study entry.
NCT03009981 ↗ A Study of Androgen Annihilation in High-Risk Biochemically Relapsed Prostate Cancer Recruiting Alliance Foundation Trials, LLC. Phase 3 2017-03-06 This is a randomized, open-label, three-arm, phase 3 study in men with biochemically recurrent prostate cancer and PSA doubling time ≤ 9 months at the time of study entry.
NCT03279250 ↗ Apalutamide and Gonadotropin-Releasing Hormone Analog With or Without Abiraterone Acetate in Treating Participants With Prostate Cancer Completed Janssen Scientific Affairs, LLC Phase 2 2017-10-13 This phase II trial studies how well apalutamide and gonadotropin-releasing hormone analog with or without abiraterone acetate work in treating participants with prostate cancer prior to surgery. Apalutamide and abiraterone acetate may stop the growth of cancer cells either by killing the cells or by blocking some of the enzymes needed for cell growth. Hormone therapy, using gonadotropin-releasing hormone analog, may fight prostate cancer by lowering the amount of testosterone the body makes. Giving apalutamide, gonadotropin-releasing hormone analog, and abiraterone acetate may work better in treating participants with prostate cancer.
NCT03279250 ↗ Apalutamide and Gonadotropin-Releasing Hormone Analog With or Without Abiraterone Acetate in Treating Participants With Prostate Cancer Completed M.D. Anderson Cancer Center Phase 2 2017-10-13 This phase II trial studies how well apalutamide and gonadotropin-releasing hormone analog with or without abiraterone acetate work in treating participants with prostate cancer prior to surgery. Apalutamide and abiraterone acetate may stop the growth of cancer cells either by killing the cells or by blocking some of the enzymes needed for cell growth. Hormone therapy, using gonadotropin-releasing hormone analog, may fight prostate cancer by lowering the amount of testosterone the body makes. Giving apalutamide, gonadotropin-releasing hormone analog, and abiraterone acetate may work better in treating participants with prostate cancer.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for Erleada

Condition Name

Condition Name for Erleada
Intervention Trials
Stage IVA Prostate Cancer AJCC v8 7
Prostate Adenocarcinoma 7
Prostate Cancer 7
Stage IIIC Prostate Cancer AJCC v8 4
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for Erleada
Intervention Trials
Prostatic Neoplasms 18
Adenocarcinoma 5
Carcinoma 4
Hypersensitivity 2
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for Erleada

Trials by Country

Trials by Country for Erleada
Location Trials
United States 149
Canada 6
China 2
Germany 1
Italy 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for Erleada
Location Trials
Texas 11
California 8
Pennsylvania 6
Ohio 6
Illinois 6
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for Erleada

Clinical Trial Phase

Clinical Trial Phase for Erleada
Clinical Trial Phase Trials
Phase 3 7
Phase 2 10
Phase 1 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for Erleada
Clinical Trial Phase Trials
Recruiting 10
Suspended 3
Active, not recruiting 2
[disabled in preview] 3
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for Erleada

Sponsor Name

Sponsor Name for Erleada
Sponsor Trials
National Cancer Institute (NCI) 9
M.D. Anderson Cancer Center 6
Janssen Scientific Affairs, LLC 5
[disabled in preview] 4
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for Erleada
Sponsor Trials
Other 17
Industry 10
NIH 9
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Johnson and Johnson
AstraZeneca
Baxter
Boehringer Ingelheim
Moodys
Mallinckrodt

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.